Skip to main content
13 search results for:

Venetoclax 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 07-06-2021 | ASCO 2021 | Conference coverage | Article

    Adding venetoclax to fulvestrant offers no extra benefit in VERONICA trial

    Adding the BCL2 inhibitor venetoclax to fulvestrant does not improve outcomes for women with estrogen receptor-positive, HER2-negative locally advanced breast cancer resistant to endocrine and CDK4/6 inhibitor treatment, say the VERONICA investigators.

  2. 24-08-2018 | Chronic lymphocytic leukemia | News | Article

    Obinutuzumab plus venetoclax shows promise for chronic lymphocytic leukemia

    Obinutuzumab and venetoclax, preceded by bendamustine debulking for high tumor loads, shows high response rates without unexpected or cumulative toxicities in patients with chronic lymphocytic leukemia, a phase II trial suggests.

  3. 03-04-2018 | Chronic lymphocytic leukemia | News | Article

    Venetoclax plus rituximab improves relapsed, refractory CLL outcomes

    Treatment with venetoclax plus rituximab results in significantly higher rates of progression-free survival than standard chemoimmunotherapy in patients with relapsed or refractory chronic lymphocytic leukemia, phase III MURANO trial results indicate.

  4. 21-12-2017 | Chronic lymphocytic leukemia | News | Article

    Venetoclax shows promise for ibrutinib-resistant CLL

    Venetoclax elicits a clinically meaningful response in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with ibrutinib, US study data show.

  5. 24-01-2018 | Leukemia | News | Article

    Venetoclax, inotuzumab ozogamicin promising in older leukemia patients

    Four study participants died within 30 days of initiating venetoclax, with one case each of sepsis, bacteremia, lung infection, and respiratory failure.

  6. 10-04-2018 | Mantle cell lymphoma | News | Article

    Ibrutinib, venetoclax oral combination shows promise for mantle cell lymphoma

    Ibrutinib plus venetoclax could together be beneficial as oral treatment for mantle-cell lymphoma, suggests a phase II study published in The New England Journal of Medicine .

  7. 04-07-2018 | FDA | News | Article
    approvalsWatch

    FDA expands indications for venetoclax, bevacizumab

    The initial approval for venetoclax in 2016 restricted the use of the drug to CLL patients who had received at least one prior therapy and harbored a 17p deletion.

  8. 17-01-2017 | Chronic lymphocytic leukemia | Article

    Venetoclax plus rituximab ‘attractive potential option’ for relapsed, refractory CLL

    Venetoclax plus rituximab is active and well tolerated in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, shows a phase Ib trial.

  9. 14-03-2018 | Article

    Advisory board comment

    Comment on: Venetoclax, inotuzumab ozogamicin promising in older leukemia patients

  10. 08-02-2018 | Acute lymphoblastic leukemia | News | Article
    News in brief

    INO-VATE analysis demonstrates benefits for younger and older ALL patients

    . © 2018 Springer Healthcare part of the Springer Nature group See also: Venetoclax, inotuzumab ozogamicin promising in older leukemia patients Olaparib, inotuzumab ozogamicin FDA approvals announced

  11. 14-03-2017 | Lymphoma | Case report | Article

    SLL and CLL

    Therefore, venetoclax was developed instead due to its higher selectivity. 

  12. 29-12-2016 | Lymphoma | Article

    The landscape of new drugs in lymphoma

    In some patients with CLL, venetoclax can result in rapid tumour lysis syndrome.

  13. 12-08-2016 | Acute lymphoblastic leukemia | Article

    A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program

    The second-generation BCL-2 inhibitor, ABT-199 (venetoclax), which has shown promise in the treatment of chronic lymphocytic leukemia, 81 achieved objective responses in 6/21 pediatric ALL PDXs (Figure 2), 82 indicating that ALL may be less dependent than chronic lymphocytic leukemia on BCL-2.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.